Clinical Trials Browser

INDUSTRY × Carcinoma × Lapatinib × Clear all

NCT00968968 2019-06-10

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Phase 3 Terminated

37 enrolled 11 charts

Carcinoma, Neoplasms